Sidekick Health AB expanded its partnership with Pfizer Inc., adding an atopic dermatitis offering to its integrated digital therapeutics solution. The app will roll out first in the U.K., followed by Belgium, Norway, Netherlands, Sweden, France, Ireland and Japan this year.

Evotec AG and Sernova Corp. are joining forces in a bid to develop a functional cure for type 1 diabetes. The companies plan to file an IND early in 2024 for a combined cell therapy and medical device product comprising Evotec’s human beta cells, derived from the company’s induced pluripotent stem cell platform, and Sernova’s Cell Pouch delivery system, which provides transplanted cells with a vascularized, physiologically appropriate environment that enables them to secrete insulin and other hormones involved in regulating blood glucose levels.

Beacon Biosignals Inc. has teamed up with Stratus Inc., a provider of electroencephalogram (EEG) services, to improve at-home brain monitoring and neurodiagnostics using Beacon’s machine learning-driven neuroanalytics platform. The collaboration will increase opportunities for home-based studies of Alzheimer’s and other neurological diseases.

Getinge AB is acquiring 100% of the equity in fluorescence imaging company Fluoptics SAS, a company using the technology as an aid to surgery. Getinge will, through its subsidiary Getinge Infection Control SAS, acquire all outstanding shares in Fluoptics and will pay around $27 million in cash on closing the deal.

Ecential Robotics SAS and Amplitude Surgical SA reported a long-term partnership to develop a  robotic solution for knee surgery. These two French-based med-tech firms are combining their technology used for intraoperative 2D/3D imaging and surgical navigation in orthopedics.

Computational disease modeling company Cytoreason Ltd. is expanding its reach into Asia with a recent partnership with South Korean big data company Helixrus Inc., which is focused on biological big data and multiomics. The alliance will focus on leveraging Helixrus’ deep knowledge of the South Korean pharmaceutical market, and extensive network of relationships in Asian markets, to highlight Cytoreason’s capabilities in prioritizing new targets, finding biomarkers, profiling combinations, stratifying patients and other use cases within the drug lifecycle.

Xbiome Inc. acquired M-201, a clinical-stage program from Assembly Biosciences Inc., to treat patients with mild to moderate ulcerative colitis as it looks to develop products to address the growing incidence of bowel disease throughout Asia. The company expects to start a phase Ib trial of the oral live biotherapeutic product in the U.S. in 2022 and also plans to run clinical trials in China.

Acutus Medical Inc. is selling its left-heart access portfolio to Medtronic plc in a deal worth upwards of $50 million. The portfolio of devices includes a line of sheath-compatible septal crossing devices and steerable sheaths. Under the terms of the agreement, Medtronic will make an upfront cash payment to Acutus of $50 million and additional undisclosed payments based on milestones and future sales.

Cochlear Ltd. will acquire Danish hearing implant company Oticon Medical A/S for AU$170 million (US$121 million) after parent company the Demant Group said it planned to exit its hearing implants business. Cochlear CEO Dig Howitt said that Oticon Medical is expected to add AU$75 to AU$80 million to Sydney-based Cochlear’s annual revenue, although Oticon Medical is currently “loss making.” In 2021, Demant’s hearing Implants saw revenue of $73 million.